Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. (PRPH) generates a steady flow of company news across biotech, genomics, and consumer health. Its press releases and regulatory disclosures cover developments in molecular diagnostics, whole genome sequencing, OTC dietary supplements, capital markets activity, and strategic initiatives. For investors and followers of PRPH, this news stream provides insight into how the company is advancing its programs and managing its capital structure.
A major news theme for ProPhase is the BE-Smart Esophageal Cancer Test. Company announcements describe peer-reviewed validation studies conducted with Mayo Clinic, publication in leading gastroenterology journals, and plans for commercialization and clinical integration. Updates often detail BE-Smart’s performance metrics, its role in Barrett’s Esophagus risk stratification, and steps toward broader adoption and reimbursement discussions.
Another recurring topic is genomics and Nebula Genomics. ProPhase’s news highlights its whole genome sequencing offerings and the positioning of Nebula Genomics as a consumer genomics platform with a large and diverse DNA dataset. Releases also discuss related consumer health initiatives, including DNA Complete and DNA Expand product lines, within the company’s genomics and wellness strategy.
Capital structure and financing updates are also prominent in PRPH news. Recent items include information on senior secured convertible notes and warrants registered via an S-1, an at-the-market sales agreement, a 1-for-10 reverse stock split to address listing requirements, and shareholder communications about trading activity, convertible debt conversions, and the transition from Nasdaq to the OTC market. These disclosures explain how ProPhase is addressing liquidity, managing dilution, and aligning its share structure with strategic goals.
Strategic and legal developments appear as well, such as a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., the Crown Medical Collections receivables recovery initiative, and updates on legal matters disclosed in Form 8-K filings. For readers tracking PRPH, this news page aggregates these diverse updates in one place, making it easier to follow the company’s diagnostics, genomics, consumer health, and corporate actions over time.
ProPhase Labs (NASDAQ: PRPH) provided a progress report on its cancer co-therapy program, Linebacker-1 (LB-1), developed by its subsidiary ProPhase BioPharma. LB-1 targets PIM kinase receptors and is designed to enhance traditional chemotherapy effectiveness while reducing toxicity. The company collaborated with Dana-Farber Cancer Institute to explore effective combinations with LB-1, focusing on various cancer types. Initial studies show promising results, with plans for animal studies to complete by Q2 2023 and IND application submission targeted for mid-2024. Development costs are estimated between $3 million and $5 million.
ProPhase Labs (NASDAQ: PRPH) has successfully acquired exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic test from Stella Diagnostics for approximately $4.6 million. This test aims to enhance early detection of esophageal cancer and is expected to reduce unnecessary endoscopies. The BE-Smart test has shown over 99% sensitivity and specificity in preliminary trials. ProPhase anticipates commercializing the test within 18 months and targets reimbursement rates between $1,000 - $3,000, addressing a multi-billion dollar market in the U.S.
ProPhase Labs (NASDAQ: PRPH) has entered into an asset purchase agreement to acquire world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic test from Stella Diagnostics for approximately $4.5 million in cash and stock. An additional $2 million may be issued based on future revenue milestones. The BE-Smart test, showing over 99% sensitivity and specificity, aims for early esophageal cancer detection and could reduce unnecessary endoscopies. The acquisition is pending Stella shareholders' approval and is expected to close in early January 2023.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced its presentation at the Planet MicroCap Showcase: VIRTUAL 2022 on December 7, 2022, at 2:30 PM EST, hosted by CEO Ted Karkus. The event will be accessible via a live webcast. ProPhase is a diversified diagnostics, genomics, and biotech company, leveraging CLIA lab services for whole genome sequencing and traditional molecular testing, including COVID-19. The company aims to expand its clinical and genomics testing capabilities, while also focusing on developing new drugs and collaborations in the medical field.
ProPhase Labs (NASDAQ: PRPH) reported strong Q3 2022 results, achieving a record net revenue of $24.2 million, marking a 155% increase year-over-year. The company also noted a net income of $1.0 million, a turnaround from a $4.0 million loss in Q3 2021. Adjusted EBITDA stood at $6.3 million, a significant improvement from a loss of $1.3 million in the previous year. Cash and equivalents totaled $26.5 million. The company is expanding its services, collaborating with G42 Healthcare, and developing a cancer treatment with Dana-Farber Cancer Institute.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced a two-year collaboration with Dana-Farber Cancer Institute to develop Linebacker-1 (LB-1), a small molecule aimed at enhancing chemotherapy. This partnership will explore LB-1's tumoricidal effects when co-administered with traditional chemotherapy agents in vitro and in vivo. The project has a budget of $2-5 million over 18 months, targeting preclinical studies and a Phase 1 human clinical trial. ProPhase expects LB-1 to have multi-billion-dollar potential in oncology.
ProPhase Labs (NASDAQ: PRPH) announced its participation in the Q4 Investor Summit Conference on November 14, 2022, at the Sheraton New York Times Square Hotel. CEO Ted Karkus will present at 3:00 PM ET. The conference is complimentary for qualified investors, with 1x1 meetings available. The company focuses on diagnostics, genomics, and biotech solutions, leveraging its CLIA lab services for whole genome sequencing and providing COVID-19 testing among others.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 10, 2022, at 11:00 a.m. Eastern time to discuss its third quarter results for the period ended September 30, 2022. A press release with detailed results will be issued prior to the call. The call will be hosted by CEO Ted Karkus and feature a Q&A session. Participants can register online or use dial-in numbers for access. The call will also be broadcast live and accessible for replay.
ProPhase Labs, Inc. (NASDAQ: PRPH) has announced a collaboration with G42 Healthcare to enhance genomic sequencing capabilities. This partnership aims to create an advanced genomic sequencing facility in the U.S. and explore opportunities in genomic data sharing and artificial intelligence. The initiative focuses on the development of personalized medical treatments, targeting high-growth markets globally. ProPhase plans to expand its New York headquarters and intends to leverage its CLIA lab services for whole genome sequencing and diagnostics, aiming for operational efficiencies and cost savings.
ProPhase Labs, Inc. (NASDAQ: PRPH) will participate in The ThinkEquity Conference on October 26, 2022, at the Mandarin Oriental Hotel in New York. CEO Ted Karkus is scheduled to present at 11:30 AM ET. The event will include opportunities for one-on-one investor meetings and will also be live-streamed. ProPhase Labs focuses on diagnostics, genomics, and biotech, leveraging CLIA lab services for whole genome sequencing and COVID-19 testing. Visit www.ProPhaseLabs.com for more information.
FAQ
What is the current stock price of Prophase Labs (PRPH)?
What is the market cap of Prophase Labs (PRPH)?
